Stéphanie Pépin

633 citations

23 papers · 507 indexed · h-index 15

Co-authors: Camille Salamand Mélanie Saville Yves Donazzolo Alen Jambrecina Martin Dupuy Sandrine Samson Jean‐Michel Scherrmann Charles Lutsch
Topics: Influenza Virus Research Studies (22 papers)Respiratory viral infections research (15 papers)Immune Response and Inflammation (6 papers)
Cited by: Epidemiology Infectious Diseases Health
Journals: PLoS ONE The Lancet Infectious Diseases Pharmaceutical Research
Partner nations: France United States Finland

In The Last Decade

Stéphanie Pépin

22 papers receiving 492 citations

Peers

Countries citing papers authored by Stéphanie Pépin

Since Specialization

Citations

This map shows the geographic impact of Stéphanie Pépin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Pépin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Pépin more than expected).

Fields of papers citing papers by Stéphanie Pépin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Pépin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Pépin. The network helps show where Stéphanie Pépin may publish in the future.

Co-authorship network of co-authors of Stéphanie Pépin

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Pépin. A scholar is included among the top collaborators of Stéphanie Pépin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Pépin. Stéphanie Pépin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study 2025 ·The Lancet Infectious Diseases ·Pedro M. Folegatti,Stéphanie Pépin,(unknown),Katherine Fries,(unknown),Stephanie K. See,Brandon Essink,Todd Bertoch,(unknown),(unknown),M. Konieczny,(unknown),(unknown)	2
2	Development of Real-Time Surveillance for Serious Adverse Events in a Pragmatic Clinical Trial Using National Registers in Finland 2024 ·Clinical Epidemiology ·(unknown),Arto A. Palmu,(unknown),Sangita Kulathinal,Kari Auranen,Ritva Syrjänen,Heta Nieminen,Tamala Mallett Moore,Stéphanie Pépin,Jukka Jokinen	0
3	High‐Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults 2024 ·Influenza and Other Respiratory Viruses ·Arto A. Palmu,Stéphanie Pépin,Ritva Syrjänen,Karine Mari,Tamala Mallett Moore,Jukka Jokinen,Heta Nieminen,Terhi Kilpi,Sandrine Samson,(unknown)	5
4	Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trial 2021 ·American Heart Journal ·Rosalind Hollingsworth,Arto A. Palmu,Stéphanie Pépin,Martin Dupuy,Anju Shrestha,Jukka Jokinen,Ritva Syrjänen,Joshua Nealon,Sandrine Samson,(unknown)	14
5	Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial 2021 ·Human Vaccines & Immunotherapeutics ·Stéphanie Pépin,Jean‐François Nicolas,Henryk Szymański,Isabel Leroux‐Roels,Thomas Schaum,Marc J. M. Bonten,Giancarlo Icardi,Anju Shrestha,(unknown),(unknown)	25
6	Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial 2019 ·BMC Infectious Diseases ·Clotilde El Guerche‐Séblain,Annick Moureau,Camille Schiffler,Martin Dupuy,Stéphanie Pépin,Sandrine Samson,Philippe Vanhems,François Schellevis	15
7	Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the Northern and Southern Hemispheres 2019 ·Vaccine ·Stéphanie Pépin,Sandrine Samson,Fabián P. Alvarez,Martin Dupuy,(unknown),(unknown)	6
8	Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial 2019 ·Human Vaccines & Immunotherapeutics ·(unknown),José Luis Arredondo-Garcı́a,(unknown),(unknown),Martin Dupuy,Céline Petit,(unknown),Enrique Rivas,Sanjay Gurunathan,(unknown),Stéphanie Pépin	3
9	Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6–35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres 2018 ·Vaccine ·Stéphanie Pépin,Martin Dupuy,Charissa Borja-Tabora,May Montellano,Lulu Bravo,(unknown),(unknown),Doris Maribel Rivera-Medina,Clare Cutland,(unknown),Javier Díez‐Domingo,(unknown),Federico Martinón‐Torres,Efimia Papadopoulou‐Alataki,(unknown),(unknown),Sanjay Gurunathan,(unknown)	43
10	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults 2016 ·PLoS ONE ·Rajeka Lazarus,Sarah Kelly,Matthew D. Snape,Corinne Vandermeulen,Merryn Voysey,Karel Hoppenbrouwers,(unknown),Pierre Van Damme,Stéphanie Pépin,Isabel Leroux‐Roels,Geert Leroux‐Roels,Andrew J. Pollard	3
11	Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial 2015 ·Vaccine ·(unknown),Terry Nolan,Charissa Borja-Tabora,(unknown),(unknown),Ferdinandus J. de Looze,(unknown),Stephen Hall,Martin Dupuy,Yanee Hutagalung,Stéphanie Pépin,Mélanie Saville	43
12	Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults 2013 ·Vaccine ·Stéphanie Pépin,Yves Donazzolo,Alen Jambrecina,Camille Salamand,Mélanie Saville	77
13	Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age 2012 ·Human Vaccines & Immunotherapeutics ·Timo Vesikari,Stéphanie Pépin,Inca Kusters,Agnès Hoffenbach,Martine Denis	24
14	Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine 2010 ·Human Vaccines ·Diane van der Vliet,Stéphanie Pépin,Michel Lambert,(unknown),Yves Donazzolo,Martin Dupuy,(unknown),Martine Denis	15
15	Heterosubtype Neutralizing Responses to Influenza A (H5N1) Viruses Are Mediated by Antibodies to Virus Haemagglutinin 2009 ·PLoS ONE ·Jean‐Michel Garcia,Stéphanie Pépin,Nadège Lagarde,S. K. Edward,Frederick R. Vogel,Kwok Hung Chan,Susan S. Chiu,Malik Peiris	36
16	Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults 2009 ·Vaccine ·Isabel Leroux‐Roels,Marie Van der Wielen,(unknown),Corinne Vandermeulen,Rajeka Lazarus,Matthew D. Snape,Tessa M. John,Christophe Carré,Nolwenn Nougarede,Stéphanie Pépin,Geert Leroux‐Roels,Karel Hoppenbrouwers,Andrew J. Pollard,Pierre Van Damme	20
17	Safety, Humoral and Cell Mediated Immune Responses to Two Formulations of an Inactivated, Split-Virion Influenza A/H5N1 Vaccine in Children 2008 ·PLoS ONE ·Tawee Chotpitayasunondh,Usa Thisyakorn,Chitsanu Pancharoen,Stéphanie Pépin,Nolwenn Nougarede	30
18	Cross‐neutralisation of antibodies elicited by an inactivated split‐virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains 2007 ·Influenza and Other Respiratory Viruses ·Katja Höschler,Robin Gopal,Nick Andrews,Mélanie Saville,Stéphanie Pépin,John Wood,Maria Zambon	14
19	Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip® 2005 ·Vaccine ·(unknown),Camille Salamand,Grenville Marsh,(unknown),Stéphanie Pépin,Philippe Saliou	30
20	Snake F(ab′)2 Antivenom from Hyperimmunized Horse: Pharmacokinetics Following Intravenous and Intramuscular Administrations in Rabbits 1995 ·Pharmaceutical Research ·Stéphanie Pépin,Charles Lutsch,(unknown),Jean‐Michel Scherrmann	33

About Stéphanie Pépin

Stéphanie Pépin is a scholar working on Epidemiology, Immunology and Infectious Diseases, having authored 23 papers that have together received 507 indexed citations. Recurring topics across this work include Influenza Virus Research Studies (22 papers), Respiratory viral infections research (15 papers) and Immune Response and Inflammation (6 papers). The work is most often cited by research in Epidemiology (423 citations), Infectious Diseases (163 citations) and Health (67 citations). Stéphanie Pépin has collaborated with scholars based in France, United States and Finland. Frequent co-authors include Camille Salamand, Mélanie Saville, Yves Donazzolo, Alen Jambrecina, Martin Dupuy, Sandrine Samson, Jean‐Michel Scherrmann, Charles Lutsch, Nolwenn Nougarede and Martine Denis. Their work appears in journals such as PLoS ONE, The Lancet Infectious Diseases and Pharmaceutical Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact